gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Tumor necrosis factor receptor superfamily, member 8

CD30, Ki-1
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CD20, HAD, CAN, CD4, ALK
Papers using CD30 antibodies
Follicular dendritic cell sarcoma in the lymph nodes of the neck
Supplier
Adam Patrick et al., In Diagnostic Pathology, 2006
... CD30DAKO ...
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
Supplier
Stein Harald et al., In Virchows Archiv, 2001
... CD30BerH2Citrate1:50Dako ...
ClinicalTrials.gov: A Service of the U.S. National Institute of Health
Supplier
Winer Eric et al., In Journal of Hematology & Oncology, 1996
... The samples were also stained for CD30 (Novocastra; dilution 1:100) and EMA (Dako; dilution 1:50), which are ...
Follicular dendritic cell tumor of the liver. Evidence for an Epstein-Barr virus-related clonal proliferation of follicular dendritic cells
Supplier
Vasef Mohammad A. et al., In Journal of Hematopathology, 1995
... CD34, ALK protein (Ventana Medical Systems, Tucson, AZ, USA); smooth muscle actin (SMA), CD20, CD21, CD30, epithelial membrane antigen (EMA) (Dako, Carpinteria, CA, USA); CD35 ...
more suppliers
Papers on CD30
Lymphomatoid Papulosis Type D: Report of a Case in a Child and Review of the Literature.
New
Scott et al., Rochester, United States. In Pediatr Dermatol, Feb 2016
UNASSIGNED: Lymphomatoid papulosis (LyP) is a cutaneous CD30-positive T-cell lymphoproliferative disorder that occurs primarily in adults and presents with crops of papules that become necrotic and spontaneously regress.
Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of "germinotropic" lymphoproliferative disorder.
New
Facchetti et al., Brescia, Italy. In Virchows Arch, Feb 2016
Lymph nodes showed an effaced nodular architecture with abnormal B follicles colonized by EBV+ large, pleomorphic atypical cells, including Reed-Sternberg-like cells, showing an activated B cell phenotype (CD10-FOXP1-Bcl6-IRF4+ or CD10-FOXP1+Bcl6+IRF4+) and intense expression of CD30.
Primary hepatic Epstein-Barr virus-associated CD30-positive peripheral T-cell lymphoma of cytotoxic phenotype.
New
Qing et al., Torrance, United States. In Exp Mol Pathol, Feb 2016
By immunohistochemistry, the lymphoma cells expressed CD2, CD3, CD8, CD30, CD43, CD45, granzyme B, TIA-1, and negative for CD4, CD5, CD7, CD56, βF1, ALK-1, and B-cell markers.
Primary Cutaneous Lymphoma-Associated Pseudoepitheliomatous Hyperplasia Masquerading as Squamous Cell Carcinoma in a Young Adult.
New
Ghanadan et al., Tehrān, Iran. In Acta Med Iran, Dec 2015
Primary cutaneous anaplastic large cell lymphoma is a T-cell malignancy with atypical CD30 positive lymphocytes.
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
New
Impact
Kim et al., Birmingham, United Kingdom. In J Clin Oncol, Dec 2015
PATIENTS AND METHODS: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin.
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
New
Impact
Horwitz et al., Stanford, United States. In J Clin Oncol, Dec 2015
PURPOSE: In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sézary syndrome (SS) is quite variable.
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
New
Impact
Talpur et al., Houston, United States. In J Clin Oncol, Dec 2015
PURPOSE: Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30(+) receptors.
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.
Review
New
Kim et al., Ch'unch'ŏn, South Korea. In Biomol Ther (seoul), Nov 2015
Advancements in these core antibody-drug conjugate technology are reflected by recent approval of Adectris(®) (anti-CD30-drug conjugate) and Kadcyla(®) (anti-HER2 drug conjugate).
Novel agents for the treatment of Hodgkin lymphoma.
Review
New
Mehta et al., New Brunswick, United States. In Expert Rev Hematol, Oct 2015
Brentuximab vedotin is an antibody drug conjugate targeting CD30 with high response rates in HL.
[Human herpesvirus 8-negative primary effusion lymphoma-like lymphoma with t(8;14)(q24;q32)].
Review
New
Aiba et al., In Rinsho Ketsueki, Aug 2015
The pathological examination of the pleural effusion showed proliferation of atypical large lymphoid cells, which were positive for CD19, CD20, CD10, CD38, CD7, BCL2 and BCL6 but negative for CD5, CD30, MUM1, surface immunoglobulin, HHV-8 and EBV.
Successful long-term control of recurrent primary central nervous system anaplastic large cell lymphoma after autologous hematopoietic stem cell transplantation with concurrent whole brain and spinal cord radiotherapy.
Review
Kobayashi et al., Nagano, Japan. In Rinsho Ketsueki, 2014
Cerebrospinal fluid (CSF) cytology showed large atypical cells expressing CD2, cytoplasmic CD3, CD7, CD13 and CD30.
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.
Review
Morabito et al., Reggio di Calabria, Italy. In J Immunol Res, 2014
Based on recent knowledge of HL pathology, biology, and immunology, antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints are currently explored.
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Impact
Shustov et al., Houston, United States. In J Clin Oncol, 2014
This phase I open-label study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP or in combination with CHP (CHOP without vincristine) as front-line treatment in patients with CD30(+) PTCL.
Primary extranodal NK/T-cell lymphoma of the lung: Mimicking bronchogenic carcinoma.
Shen et al., Taipei, Taiwan. In Thorac Cancer, 2014
The pathology revealed atypical lymphoid cell infiltration, which is immunoreactive for cytoplasmic CD3, CD30 and CD56, but not reactive for CK and CD20.
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Impact
Ansell et al., Houston, United States. In Lancet Oncol, 2013
Main entry criteria were newly diagnosed, treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Cooperative Oncology Group performance status of two or less.
CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease.
GeneRIF
Tani et al., Fukuoka, Japan. In Dig Dis Sci, 2012
CD30L/CD30 pathway acts as an accelerator of enteritis in a murine disease model
Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases.
GeneRIF
Kutzner et al., Zürich, Switzerland. In Am J Surg Pathol, 2012
Describe pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells sharing features of lymphomatoid papulosis and other cutaneous lymphomas.
Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation.
GeneRIF
Tan et al., Fuzhou, China. In Transpl Immunol, 2012
higher levels of soluble protein in kidney transplant recipients suffering graft loss
The expression of CXCR3 and CD30 in mycosis fungoides.
GeneRIF
Nikoo, Tehrān, Iran. In Arch Iran Med, 2012
Scattered or diffuse CD30 expression in T-MF was not associated with an absence of CXCR3 expression.
Targeted repression of overexpressed CD30 downregulates NF-kappaB and ERK1/2 pathway in Hodgkin lymphoma cell lines.
GeneRIF
Horie et al., Japan. In Oncol Res, 2010
indicate that CD30 is involved in the tumorigenic process of Hodgkin lymphoma (HL), and that it may be useful as a therapeutic target for the treatment of HL
More papers using CD30 antibodies
Skeletal complications in hairy cell leukemia: diagnosis and therapy
Supplier
Sohani Aliyah R. et al., In Journal of Hematopathology, 1987
share on facebooktweetadd +1mail to friends